Plate Nº 73 · recorded November 10, 2026
Health & Medicine ResearchReported finding
Semaglutide Beats Placebo in Fatty Liver Trial: 63% vs 34%
A 72-week trial of 800 MASH patients found weekly semaglutide resolved liver inflammation in 63% of cases versus 34% on placebo, with scarring improving in 37%.
By Nathan Brooks3 min read603 words
In brief
- 63% of MASH patients on semaglutide had liver inflammation resolve without worsening scarring, versus 34% on placebo.
- Liver scarring improved in 37% of the semaglutide group versus 22% on placebo over 72 weeks.
- The ESSENCE trial interim analysis covered 800 participants, published in The New England Journal of Medicine.
- The trial was led by teams including King's College London and Virginia Commonwealth University and funded by Novo Nordisk.
- Results are interim; longer follow-up is needed to confirm prevention of liver failure and major complications.
Roughly 63% of patients with a serious fatty liver disease saw their liver inflammation resolve on weekly semaglutide injections, compared with about 34% on placebo. That near-doubling is the headline result of the ESSENCE trial, published in The New England Journal of Medicine, and it could matter for a condition with very few treatment options.
The trial tested semaglutide — the drug already approved for diabetes and weight management — against metabolic dysfunction-associated steatohepatitis, or MASH. In plain terms, MASH means excess fat in the liver plus inflammation and damage that can progress to dangerous scarring. Obesity and poor blood sugar regulation are major drivers of the disease.
What did the trial measure?
Researchers enrolled patients across many countries and medical centers and followed them for 72 weeks. The new figures come from an interim analysis covering 800 participants. They compared weekly semaglutide injections with placebo injections.
Two results stand out:
- Inflammation resolved without worsening scarring in about 63% of the semaglutide group versus about 34% of the placebo group.
- Liver scarring itself improved in about 37% of the semaglutide group versus about 22% of the placebo group.
The scarring figure is the more surprising one. It suggests the medicine may affect more than body weight alone.
How does the drug work?
Semaglutide acts on a hormone pathway that regulates appetite and blood sugar. Those effects on eating and metabolism, in turn, may reduce stress on the liver. Participants did lose weight and improved on several liver-related measurements, which fits the mechanism — but the tissue-level improvements went beyond what weight numbers alone would predict.
The study was led by an international research team including scientists at King's College London and Virginia Commonwealth University. Novo Nordisk, the company that makes semaglutide, funded the trial — a common arrangement in drug research, and one readers should weigh alongside the findings.
Why tissue samples matter
The researchers didn't rely on blood tests alone. They assessed inflammation and scarring using actual liver tissue samples. That detail matters: improvements in weight or liver enzymes don't always mean the underlying tissue damage has actually healed.
By looking at the tissue directly, the trial provides stronger evidence that the drug changed the disease process, not just the numbers on a lab report.
What are the caveats?
Plenty, and the researchers say so themselves. The results are an interim analysis of an ongoing trial, not the final word. Longer follow-up is still needed to answer the biggest question: whether these early improvements actually prevent liver failure and other major health problems down the line. Participants remain under monitoring to see if the gains last.
There's also the practical reality of side effects. Like any medicine, semaglutide isn't suitable for everyone. People with liver disease should talk to a qualified clinician before starting or changing any medication.
One more nuance: patients in the trial also received advice on healthy habits. Medicines are only one part of managing metabolic liver disease, and the trial design reflects that.
Why it still counts as an advance
For a disease with limited options, the finding that a familiar, already-prescribed drug may address both the metabolic problems and the liver injury of MASH is genuinely encouraging. Preventing worsening liver damage could reduce the risk of serious complications later in life.
It's not a cure, and it's not final. But a doubling of inflammation resolution — 63% against 34% — is the kind of number that changes conversations between doctors and patients. The next round of data, with longer follow-up, will tell us how durable those gains really are.
via knowridge.com (Source)
More from Nathan Brooks
Show full bio
Market editor covering companies, deals and strategy in general science news at SciBeat.
325 articles
Nearby plates
- SELECT Long-Term Weight Loss Data Published in Nature
- Phase 3 trial tests survodutide for obesity-linked fatty liver disease
- High IgA Levels Identify a High-Risk Subtype of Fatty Liver Disease
- Muscle-Sparing Antibody Halves Lean Mass Loss from Semaglutide
- NEJM Publishes Oral Semaglutide Cardiovascular Outcome Study